FMP
XOMA Corporation
XOMA
NASDAQ
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
24.32 USD
0.88 (3.62%)
XOMA Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-13.75M
-18.16M
-12.88M
22.68M
Net Income
-13.82M
-40.83M
-17.1M
15.8M
Depreciation & Amortization
216k
900k
104k
7k
Deferred Income Taxes
-5.66M
0
0
1.31M
Stock Based Compensation
10.31M
9.1M
3.61M
6.2M
Change in Working Capital
-2.79M
-3.53M
-181k
-886k
Accounts Receivable
0
0
208k
54k
Inventory
0
0
0
-63k
Accounts Payable
1.6M
-523k
1.84M
765k
Other Working Capital
-4.39M
-3.01M
-2.23M
-1.64M
Other Non-Cash Items
-2.01M
16.2M
694k
255k
CF from Investing Activities
-28.26M
-711k
-20.22M
-26.5M
Investments in Property, Plant & Equipment
-20k
-17k
-23.25M
-26.5M
Net Acquisitions
18.93M
0
-20.22M
0
Investment Purchases
-3.24M
0
0
0
Sales/Maturities of Investments
0
0
0
0
Other Investing Activites
-43.93M
-694k
23.25M
-26.5M
CF from Financing Activities
-11.13M
120.59M
-4.45M
12.84M
Debt Repayment
-6.9M
130M
-1.02M
-21.35M
Common Stock Issued
0
0
2.42M
38.2M
Common Stock Repurchased
-13k
-148k
-1.4M
-488k
Dividends Paid
-5.47M
-5.47M
-5.47M
-3.5M
Other Financing Activites
1.26M
-3.79M
1.02M
38.17M
Free Cash Flow
-13.77M
-18.18M
-36.13M
-3.82M
Operating Cash Flow
-13.75M
-18.16M
-12.88M
22.68M
Capital Expenditures
-20k
-17k
-23.25M
-26.5M
Cash at Beginning of Period
159.55M
57.83M
95.38M
86.36M
Cash at End of Period
106.42M
159.55M
57.83M
95.38M
Net Change In Cash
-53.13M
101.72M
-37.55M
9.01M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-1.22B
-1.18B
-1.17B
-1.18B
Net Income
-13.82M
-40.83M
-17.1M
15.8M
Stock Repurchases
-13k
-148k
-1.4M
-488k
Dividend Paid
-5.47M
-5.47M
-5.47M
-3.5M
Retained Earnings
-1.24B
-1.22B
-1.18B
-1.17B
Other Distributions
-19.32M
-46.45M
-23.97M
11.81M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
351k
403k
36k
213k
Annual Depreciation
216k
900k
274k
167k
Capital Expenditure
-20k
-17k
-23.25M
-26.5M
Net PPE
155k
-480k
23.01M
26.55M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
